Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).

Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, Swymelar S, Dvir D, Xue Z, Torguson R.

J Interv Cardiol. 2013 Apr;26(2):107-13. doi: 10.1111/joic.12005. Epub 2012 Dec 13.

PMID:
23240743
2.

Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

Shah A, Feldman DN.

Vasc Health Risk Manag. 2012;8:115-23. doi: 10.2147/VHRM.S23491. Epub 2012 Feb 27. Review.

3.

Cost effectiveness of anticoagulation in acute coronary syndromes.

Latour-Pérez J, de-Miguel-Balsa E.

Pharmacoeconomics. 2012 Apr;30(4):303-21. doi: 10.2165/11589290-000000000-00000. Review.

PMID:
22409291
4.

Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial.

Capranzano P, Dangas G.

Expert Rev Cardiovasc Ther. 2012 Apr;10(4):411-22. doi: 10.1586/erc.12.24. Review.

PMID:
22458574
5.

Bivalirudin in percutaneous coronary intervention, is it the anticoagulant of choice?

Mahmoud A, Saad M, Elgendy AY, Abuzaid A, Elgendy IY.

Cardiovasc Ther. 2015 Aug;33(4):227-35. doi: 10.1111/1755-5922.12124. Review.

PMID:
25879426
6.

The bivalirudin paradox: high evidence, low use.

De Servi S, Mariani G, Mariani M, D'Urbano M.

J Cardiovasc Med (Hagerstown). 2013 May;14(5):334-41. doi: 10.2459/JCM.0b013e32835f1915. Review.

PMID:
23442811
7.

Safety of bivalirudin in patients with coronary artery disease.

Abdel-Wahab M, Richardt G.

Expert Opin Drug Saf. 2012 Jan;11(1):141-50. doi: 10.1517/14740338.2012.628312. Epub 2011 Oct 17. Review.

PMID:
21999110
8.

Anticoagulation for acute coronary syndromes: from heparin to direct thrombin inhibitors.

Lepor NE.

Rev Cardiovasc Med. 2007;8 Suppl 3:S9-17. Review.

PMID:
17917621
9.
10.

Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.

Simpson EL, Fitzgerald P, Evans P, Tappenden P, Kalita N, Reckless JP, Bakhai A.

Pharmacoeconomics. 2013 Apr;31(4):269-75. doi: 10.1007/s40273-013-0036-7. Review.

PMID:
23512147
11.

Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention.

Mahmoudi M, Waksman R.

Minerva Cardioangiol. 2012 Feb;60(1):95-100. Review.

PMID:
22322577
12.

Bivalirudin: a pharmacoeconomic profile of its use in patients with acute coronary syndromes.

Lyseng-Williamson KA.

Pharmacoeconomics. 2011 Apr;29(4):343-59. doi: 10.2165/11206360-000000000-00000. Review.

PMID:
21395353
13.

Clinical applications of bivalirudin in the cardiac catheterization laboratory.

Thompson KA, Philip KJ, Schwarz ER.

J Cardiovasc Pharmacol Ther. 2011 Jun;16(2):140-9. doi: 10.1177/1074248410385682. Epub 2010 Nov 19. Review.

PMID:
21097669
14.

Bivalirudin: a direct thrombin inhibitor.

Gladwell TD.

Clin Ther. 2002 Jan;24(1):38-58. Review.

PMID:
11833835
15.

How to reduce mortality in ST-elevation myocardial infarction patients treated with primary percutaneous coronary interventions: cut the bleeding.

De Servi S, Mariani G, Mariani M, D'Urbano M.

Curr Med Res Opin. 2013 Mar;29(3):189-94. doi: 10.1185/03007995.2013.770389. Epub 2013 Jan 31. Review.

PMID:
23350949
16.

Bivalirudin in percutaneous coronary intervention.

Lehman SJ, Chew DP.

Vasc Health Risk Manag. 2006;2(4):357-63. Review.

17.

The clinical and economic impact of bivalirudin for percutaneous coronary intervention.

Malik N, Gershlick AH.

Expert Rev Pharmacoecon Outcomes Res. 2013 Dec;13(6):699-706. doi: 10.1586/14737167.2013.844650. Review.

PMID:
24219045
18.

Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis.

Huang FY, Huang BT, Peng Y, Liu W, Zhao ZG, Wang PJ, Zuo ZL, Zhang C, Liao YB, Luo XL, Meng QT, Chen C, Huang KS, Chai H, Li Q, Chen M, Zhu Y.

Angiology. 2015 Oct;66(9):845-55. doi: 10.1177/0003319715568972. Epub 2015 Jan 29. Review.

PMID:
25635117
19.

Transradial versus transfemoral percutaneous coronary intervention in acute coronary syndromes: re-evaluation of the current body of evidence.

Lee MS, Wolfe M, Stone GW.

JACC Cardiovasc Interv. 2013 Nov;6(11):1149-52. doi: 10.1016/j.jcin.2013.08.003. Review.

20.

New developments in parenteral anticoagulation for arterial and venous thromboembolism.

van Es N, Bleker SM, Büller HR, Coppens M.

Best Pract Res Clin Haematol. 2013 Jun;26(2):203-13. doi: 10.1016/j.beha.2013.07.010. Epub 2013 Jul 21. Review.

PMID:
23953908
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk